Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Tolerability of Fenofibrate in Primary Biliary Cholangitis
NCT07104201Phase 1Active, not recruiting
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Mar 2025
- Primary completion
- Mar 2035
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fenofibrate in primary biliary cholangitis (PBC), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Treatment Emergent Adverse Events at 120 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
fenofibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT07104201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104201.